Will Access To HCV Meds Improve After Harvoni Approval?
Participants at AASLD/EASL special meeting on HCV complain that payers have limited coverage to only the sickest patients. The approval of Harvoni, which despite criticisms of its pricing will be much cheaper than Sovaldi/Olysio combination therapy, is expected to ease access for broader coverage.
You may also be interested in...
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Execs On The Move: Medical Microinstruments Gets New CEO; Changes At iRhythm; Aethlon Makes A Promotion
Corindus Vascular Robotics CEO made a lateral move to Medical Microinstruments; iRhythm hires a new CEO, while the former CEO stays on as a director; Aethlon promotes a director to chief business officer; and more.